FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030744594> ?p ?o ?g. }

• W3030744594 abstract "e13674 Background: BRCA germline (gBRCA) mutations occur in 11-15% of women with unselected ovarian cancers (OC), whereas somatic BRCA (sBRCA) mutations occur in approximately 5-7% of cases. The impact of sBRCA mutations on OC outcome is still debated. Methods: With the aim to explore the prognostic role of sBRCA mutations, the BRCA mutational status of 149 non-mucinous and non-borderline OC and their clinical-pathological features were evaluated. BRCA1 and BRCA2 mutational profiles, either for sequence variants or copy number alterations, were evaluated by amplicon next-generation sequencing (NGS) technology. Results: 29 (19.5%) patients carried a gBRCA mutation (12.7% BRCA1 and 6.7% BRCA2). 26 (17.5%) patients presented a sBRCA mutation (6.7% BRCA1, 10% BRCA2, 0.6% BRCA1+BRCA2). Patients carrying a gBRCA mutation were slightly younger (57 years) than the others (60 years). The FIGO stage at the diagnosis was III-IV in 77.2% of cases, with no significant difference among subgroups. The most frequent histotype was serous for all the subgroups (93.1% in gBRCA, 84.6% in sBRCA, 77.7% in BRCA-negative, p = 0.08). 80.7% of sBRCA mutation carriers, 62.1% of gBRCA mutation carriers and 62.7% of BRCA-negative patients underwent upfront surgery (p = 0.46). 29.1% of sBRCA mutation carriers, 17.8% of gBRCA mutation carriers and 25.6% of BRCA-negative patients presented macroscopic residual disease after surgery (p = 0.68). Although non-statistically significant, gBRCA-associated OC were more likely to be platinum-sensitive (96.6%) than the other patients (92% in sBRCA and 87.1% in BRCA-negative patients). Overall, the median platinum-free interval (PFI) resulted shorter in sBRCA mutation patients compared to gBRCA and BRCA-negative patients (p = 0.051). No patient took PARP inhibitors as maintenance after the first line therapy. Also progression free survival 2 (PFS2) resulted shorter for sBRCA mutation patients (p = 0.008). Three sBRCA and 5 gBRCA mutation carriers took a PARP inhibitor as maintenance after the second line therapy. Finally, sBRCA mutated patients showed worse overall survival (OS) compared to the other subgroups (p = 0.014). Conclusions: Overall, 19.5% of OC patients presented a gBRCA mutation, while 17.5% of patients showed sBRCA mutations. sBRCA-related OC did not show significantly differences in clinical-pathological features (stage at diagnosis, histotype, time to surgery and residual after surgery). To our knowledge this is the first study showing shorter PFI, PFS2 and OS in patients carrying sBRCA mutations." @default.
• W3030744594 created "2020-06-05" @default.
• W3030744594 creator A5001356724 @default.
• W3030744594 creator A5007749764 @default.
• W3030744594 creator A5009661979 @default.
• W3030744594 creator A5011502427 @default.
• W3030744594 creator A5017572615 @default.
• W3030744594 creator A5040305422 @default.
• W3030744594 creator A5044681004 @default.
• W3030744594 creator A5057157840 @default.
• W3030744594 creator A5058796036 @default.
• W3030744594 creator A5063527377 @default.
• W3030744594 creator A5070490189 @default.
• W3030744594 creator A5077942090 @default.
• W3030744594 creator A5081849821 @default.
• W3030744594 creator A5081944716 @default.
• W3030744594 creator A5083501037 @default.
• W3030744594 creator A5089329779 @default.
• W3030744594 creator A5090026327 @default.
• W3030744594 date "2020-05-20" @default.
• W3030744594 modified "2023-09-23" @default.
• W3030744594 title "The prognostic role of somatic BRCA mutations in ovarian cancer: Preliminary results from an observational multicenter cohort study." @default.
• W3030744594 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e13674" @default.
• W3030744594 hasPublicationYear "2020" @default.
• W3030744594 type Work @default.
• W3030744594 sameAs 3030744594 @default.
• W3030744594 citedByCount "0" @default.
• W3030744594 crossrefType "journal-article" @default.
• W3030744594 hasAuthorship W3030744594A5001356724 @default.
• W3030744594 hasAuthorship W3030744594A5007749764 @default.
• W3030744594 hasAuthorship W3030744594A5009661979 @default.
• W3030744594 hasAuthorship W3030744594A5011502427 @default.
• W3030744594 hasAuthorship W3030744594A5017572615 @default.
• W3030744594 hasAuthorship W3030744594A5040305422 @default.
• W3030744594 hasAuthorship W3030744594A5044681004 @default.
• W3030744594 hasAuthorship W3030744594A5057157840 @default.
• W3030744594 hasAuthorship W3030744594A5058796036 @default.
• W3030744594 hasAuthorship W3030744594A5063527377 @default.
• W3030744594 hasAuthorship W3030744594A5070490189 @default.
• W3030744594 hasAuthorship W3030744594A5077942090 @default.
• W3030744594 hasAuthorship W3030744594A5081849821 @default.
• W3030744594 hasAuthorship W3030744594A5081944716 @default.
• W3030744594 hasAuthorship W3030744594A5083501037 @default.
• W3030744594 hasAuthorship W3030744594A5089329779 @default.
• W3030744594 hasAuthorship W3030744594A5090026327 @default.
• W3030744594 hasConcept C104317684 @default.
• W3030744594 hasConcept C121608353 @default.
• W3030744594 hasConcept C126322002 @default.
• W3030744594 hasConcept C13514818 @default.
• W3030744594 hasConcept C143998085 @default.
• W3030744594 hasConcept C2780194787 @default.
• W3030744594 hasConcept C2780427987 @default.
• W3030744594 hasConcept C501734568 @default.
• W3030744594 hasConcept C54355233 @default.
• W3030744594 hasConcept C71924100 @default.
• W3030744594 hasConcept C86803240 @default.
• W3030744594 hasConceptScore W3030744594C104317684 @default.
• W3030744594 hasConceptScore W3030744594C121608353 @default.
• W3030744594 hasConceptScore W3030744594C126322002 @default.
• W3030744594 hasConceptScore W3030744594C13514818 @default.
• W3030744594 hasConceptScore W3030744594C143998085 @default.
• W3030744594 hasConceptScore W3030744594C2780194787 @default.
• W3030744594 hasConceptScore W3030744594C2780427987 @default.
• W3030744594 hasConceptScore W3030744594C501734568 @default.
• W3030744594 hasConceptScore W3030744594C54355233 @default.
• W3030744594 hasConceptScore W3030744594C71924100 @default.
• W3030744594 hasConceptScore W3030744594C86803240 @default.
• W3030744594 hasLocation W30307445941 @default.
• W3030744594 hasOpenAccess W3030744594 @default.
• W3030744594 hasPrimaryLocation W30307445941 @default.
• W3030744594 hasRelatedWork W10586329 @default.
• W3030744594 hasRelatedWork W11513603 @default.
• W3030744594 hasRelatedWork W16403592 @default.
• W3030744594 hasRelatedWork W17587699 @default.
• W3030744594 hasRelatedWork W1836420 @default.
• W3030744594 hasRelatedWork W2174129 @default.
• W3030744594 hasRelatedWork W3251518 @default.
• W3030744594 hasRelatedWork W5863299 @default.
• W3030744594 hasRelatedWork W7720014 @default.
• W3030744594 hasRelatedWork W7726188 @default.
• W3030744594 isParatext "false" @default.
• W3030744594 isRetracted "false" @default.
• W3030744594 magId "3030744594" @default.
• W3030744594 workType "article" @default.